File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.

TitleAlemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.
Authors
Cheung, WWHwang, GYTse, EKwong, YL
Issue Date2006
PublisherFondazione Ferrata Storti.
Citation
Haematologica., 2006, v. 91 n. 5 suppl., p. ECR13 How to Cite?
AbstractA 58-year-old man with warm-antibody-mediated autoimmune hemolytic anemia (AIHA) refractory to prednisolone, azathioprine, splenectomy, rituximab and combination chemotherapy, and with unacceptably high transfusion requirement, was treated with alemtuzumab. After a cumulative dose of 883 mg of alemtuzumab, the AIHA remitted completely, with normalization of hemoglobin and transfusion-independence. The major side effect was reactivation of cytomegalovirus, which was controlled with intravenous and oral ganciclovir. This case showed that alemtuzumab might be of use in therapy-refractory AIHA.
Persistent Identifierhttp://hdl.handle.net/10722/162995
ISSN
1592-8721
2023 Impact Factor: 8.2
2023 SCImago Journal Rankings: 2.490

 

DC FieldValueLanguage
dc.contributor.authorCheung, WWen_US
dc.contributor.authorHwang, GYen_US
dc.contributor.authorTse, Een_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:26:21Z-
dc.date.available2012-09-05T05:26:21Z-
dc.date.issued2006en_US
dc.identifier.citationHaematologica., 2006, v. 91 n. 5 suppl., p. ECR13en_US
dc.identifier.issn1592-8721en_US
dc.identifier.urihttp://hdl.handle.net/10722/162995-
dc.description.abstractA 58-year-old man with warm-antibody-mediated autoimmune hemolytic anemia (AIHA) refractory to prednisolone, azathioprine, splenectomy, rituximab and combination chemotherapy, and with unacceptably high transfusion requirement, was treated with alemtuzumab. After a cumulative dose of 883 mg of alemtuzumab, the AIHA remitted completely, with normalization of hemoglobin and transfusion-independence. The major side effect was reactivation of cytomegalovirus, which was controlled with intravenous and oral ganciclovir. This case showed that alemtuzumab might be of use in therapy-refractory AIHA.en_US
dc.languageengen_US
dc.publisherFondazione Ferrata Storti.-
dc.relation.ispartofHaematologica.en_US
dc.subject.meshAnemia, Hemolytic, Autoimmune - Complications - Drug Therapy - Surgery - Therapyen_US
dc.subject.meshAntibodies, Monoclonal - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAntibodies, Monoclonal, Humanizeden_US
dc.subject.meshAntibodies, Monoclonal, Murine-Deriveden_US
dc.subject.meshAntibodies, Neoplasm - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAntigens, Cd - Immunologyen_US
dc.subject.meshAntigens, Neoplasm - Immunologyen_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshAzathioprine - Therapeutic Useen_US
dc.subject.meshBlood Transfusionen_US
dc.subject.meshCytomegalovirus - Drug Effects - Physiologyen_US
dc.subject.meshCytomegalovirus Infections - Complications - Drug Therapyen_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshGanciclovir - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshGlycoproteins - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisolone - Therapeutic Useen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshSplenectomyen_US
dc.subject.meshViremia - Complications - Drug Therapyen_US
dc.subject.meshVirus Activation - Drug Effectsen_US
dc.titleAlemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.en_US
dc.typeArticleen_US
dc.identifier.emailTse, E:ewctse@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityTse, E=rp00471en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.pmid16709521-
dc.identifier.scopuseid_2-s2.0-33745941145en_US
dc.identifier.hkuros122742-
dc.identifier.volume91en_US
dc.identifier.issue5 suppl.en_US
dc.identifier.spageECR13en_US
dc.identifier.scopusauthoridCheung, WW=8615134400en_US
dc.identifier.scopusauthoridHwang, GY=14038936500en_US
dc.identifier.scopusauthoridTse, E=7005019454en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.issnl0390-6078-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats